1. Home
  2. FPI vs REPL Comparison

FPI vs REPL Comparison

Compare FPI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmland Partners Inc.

FPI

Farmland Partners Inc.

HOLD

Current Price

$10.87

Market Cap

447.2M

Sector

Real Estate

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$14.87

Market Cap

454.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPI
REPL
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
447.2M
454.6M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
FPI
REPL
Price
$10.87
$14.87
Analyst Decision
Hold
Hold
Analyst Count
1
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
502.8K
3.1M
Earning Date
04-29-2026
05-21-2026
Dividend Yield
3.14%
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$52,178,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$133.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.21
$1.50
52 Week High
$13.23
$16.33

Technical Indicators

Market Signals
Indicator
FPI
REPL
Relative Strength Index (RSI) 73.05 54.75
Support Level $10.77 $13.81
Resistance Level $11.78 $15.71
Average True Range (ATR) 0.22 0.79
MACD 0.05 -0.21
Stochastic Oscillator 89.31 40.08

Price Performance

Historical Comparison
FPI
REPL

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: